Christopher Tormey, MD
DownloadHi-Res Photo
Cards
Appointments
Laboratory Medicine
Primary
Titles
Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Appointments
Laboratory Medicine
Primary
Titles
Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Appointments
Laboratory Medicine
Primary
Titles
Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory Medicine
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
About
Titles
Professor of Laboratory Medicine
Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory MedicineBiography
Christopher A. Tormey, MD is a pathologist (board certified in Clinical Pathology as well as Blood Banking/Transfusion Medicine) in the Department of Laboratory Medicine at Yale University. Clinically, Chris is the Medical Director of Transfusion & Apheresis Services at Yale-New Haven Hospital (New Haven, CT), also providing Clinical Pathology and Laboratory Hematology/Coagulation services at Yale-New Haven Hospital. From the research standpoint, Chris has several investigative interests including: alloimmunization to non-ABO antigens in the setting of transfusion or pregnancy; examining the platelet storage lesion; and optimizing test performance/interpretation in hemostasis assays. In addition to the above, Chris is also the Director of the Transfusion Medicine fellowship at Yale and teaches medical/PA/nursing students, residents, and fellows at the Yale School of Medicine.
Appointments
Laboratory Medicine
ProfessorPrimary
Other Departments & Organizations
- Apheresis
- Apheresis/Transfusion Service
- Blood Bank
- Laboratory Medicine
- Laboratory Medicine - Education
- VA Connecticut Clinical Laboratories
- Yale Medicine
- Yale Ventures
Education & Training
- Clinical Fellow (Transfusion Medicine)
- Yale University School of Medicine (2008)
- Resident
- Yale University School of Medicine (2007)
- MD
- New York Medical College (2004)
- BA
- University of Chicago, Chemistry (2000)
Research
Overview
Medical Subject Headings (MeSH)
Blood Coagulation Tests; Blood Group Antigens; Blood Group Incompatibility; Blood Platelet Disorders; Health Care; Platelet Function Tests
ORCID
0000-0003-1785-2245
Research at a Glance
Yale Co-Authors
Frequent collaborators of Christopher Tormey's published research.
Publications Timeline
A big-picture view of Christopher Tormey's research output by year.
Research Interests
Research topics Christopher Tormey is interested in exploring.
George Goshua, MD, MSc, FACP
Alexa Siddon, MD
Gary Stack, MD, PhD
Jeanne Hendrickson, MD
Alessandro Santin, MD
Alexander B. Pine, MD, PhD
16Publications
1,392Citations
Blood Group Antigens
Blood Group Incompatibility
Publications
2024
Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchAltmetricConceptsImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategiesFactitious disorder presenting as sickle cell disease: a case report
Jacobs J, Guarente J, Karp J, Grossman B, Ziman A, McGonigle A, Binns T, Gish T, Gorham J, Park Y, Perez-Alvarez I, Burner J, Mei Z, Ward D, Woo J, Booth G, Adkins B, Webb C, Yamada C, Lee G, Abels E, Marques M, Allen E, Fasano R, Crowe E, Tobian A, Tormey C, Bloch E. Factitious disorder presenting as sickle cell disease: a case report. The Lancet Regional Health - Americas 2024, 34: 100761. PMID: 38745885, PMCID: PMC11090869, DOI: 10.1016/j.lana.2024.100761.Peer-Reviewed Original ResearchAltmetricSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchAltmetricConceptsWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStay
2023
Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice?
Abels E, Adkins B, Cedeno K, Booth G, Allen E, Stephens L, Woo J, Tormey C, Jacobs J. Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfusion Medicine Reviews 2023, 38: 150810. PMID: 38194730, DOI: 10.1016/j.tmrv.2023.150810.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAntigen testingEvidence-based recommendationsFetal risksAlloimmunized pregnanciesPoor outcomeHemolytic diseasePractice guidelinesDecades-old practiceNarrative reviewTransfusion medicineUnnecessary riskRecent evidencePregnancyUnited StatesFetusesRiskCurrent United StatesValuable alternativeTesting algorithmObstetriciansCurrent landscapeDiseaseRecommendations
2022
Alloimmunization following antigen‐negative red blood cell transfusion
Jacobs J, Binns T, Abels E, Iyer K, Villalba C, Verma A, Sostin N, Tormey C. Alloimmunization following antigen‐negative red blood cell transfusion. Transfusion 2022, 63: 430-434. PMID: 36458330, DOI: 10.1111/trf.17208.Peer-Reviewed Case Reports and Technical NotesAltmetricMeSH Keywords and ConceptsConceptsTransfusion of RBCsRed blood cell transfusionRed blood cell alloimmunizationPrevious antigen exposureBlood cell transfusionAlloantibody specificitiesCell transfusionRBC transfusionAntigen exposureRBC alloantibodiesAntigenic stimulusDetectable titersAntigenic stimulationMyeloid neoplasmsTransfusionAlloantibodiesAlloimmunizationParticular antigenPrior exposureStimulatory eventsExact mechanismCorresponding antibodiesRBCsExposurePregnancyEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2020
Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency
Gupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.Peer-Reviewed Original ResearchEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsThe evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2019
Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity
Baine I, Bahar B, Hendrickson JE, Hudson KE, Tormey CA. Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity. Transfusion 2019, 59: 1651-1656. PMID: 30811034, DOI: 10.1111/trf.15212.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements and Community Involvement
honor President's Award
National AwardAABBDetails10/14/2023United Stateshonor ASCP Mastership (MASCP)
National AwardAmerican Society for Clinical PathologyDetails10/29/2021United Stateshonor Resident Teaching Award
Yale School of Medicine AwardDept. of Laboratory MedicineDetails06/30/2019United Stateshonor The Ellis Benson Award
National AwardAcademy of Clinical Laboratory Physicians and ScientistsDetails06/13/2015United Stateshonor 40 Under 40 Awardee
National AwardAmerican Society for Clinical PathologyDetails10/10/2014United States
Clinical Care
Overview
Christopher Tormey, MD, is a pathologist who specializes in diagnosing blood, or hematological, disorders. Some of the conditions he might diagnose include bleeding or clotting disorders, anemia, sickle cell disease, and also blood cancers, including leukemia and lymphoma. Dr. Tormey is medical director of the transfusion service at the VA Connecticut Healthcare System in West Haven.
“I help make a diagnosis through lab tests and looking at samples under a microscope,” Dr. Tormey says. “Then I work with the patient to find the best solution for them.” He explains that this could be an apheresis treatment, in which a patient’s blood is filtered and replenished with a healthy supply, or it could involve a blood plasma transfusion. “It’s rewarding to provide a definitive answer and make a meaningful contribution to a patient’s therapy,” Dr. Tormey says.
At Yale School of Medicine, Dr. Tormey is an associate professor of laboratory medicine. In his research, he investigates the immune system and the presence of certain antibodies in the blood.
Clinical Specialties
Pathology; Laboratory Medicine; Hematopathology; Hematology & Oncology
Board Certifications
Clinical Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2019
- Original Certification Date
- 2008
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- April 09, 2024
Laboratory Medicine Faculty honored as AABB 2023 President's Award Recipients
- August 11, 2022
Discoveries & Impact (August 2022)
- August 11, 2021
Discoveries & Impact (August 2021)
- December 05, 2020
Yale Cancer Center Study Shows Caplacizumab Not Cost Effective for Rare Blood Disorder
Get In Touch
Contacts
Academic Office Number
Office Fax Number
Mailing Address
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Locations
Dept. of Laboratory Medicine
Academic Office
55 Park Street, Fl 3, Rm 329D
New Haven, CT 06511
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.